MVRBF News and Press, Medivir B

2024-04-30 11:12:20 ET More on Medivir AB Historical earnings data for Medivir AB Financial information for Medivir AB Read the full article on Seeking Alpha For further details see: Medivir AB's net turnover amounted to SEK 0.5M for the period between Ja...

2023-12-06 12:40:32 ET More on Medivir AB Historical earnings data for Medivir AB Financial information for Medivir AB For further details see: Medivir says IGM Biosciences cutbacks won't impact lead product fostrox

2023-08-18 14:38:37 ET More on Medivir AB Medivir starts dosing in mid-stage study of fostrox/Lenvima combo for liver cancer Infex's antibiotic MET-X gets FDA infectious disease product status Medivir's liver drug MIV-818 gets generic name fostroxacitabine bralpamide...

2023-03-14 05:42:41 ET Medivir ( OTC:MVRBF ) said the first patient with liver cancer started treatment with its drug fostroxacitabine bralpamide (fostrox) in combination with Eisai's ( OTCPK:ESALF ) ( OTCPK:ESAIY ) Lenvima in phase 2a trial. In the Swedish c...

Medivir AB press release ( OTC:MVRBF ): Q4 GAAP EPS of -SEK 0.32. Net turnover of SEK 2.3M (-83.5% Y/Y). Liquid assets, including short-term investments amounted to SEK 117.4M at the end of the period, corresponding to a decrease of SEK 103.7M. The board proposes that no divid...

Medivir ( OTC:MVRBF ) said the U.S. Food and Drug Administration (FDA) granted qualified infectious disease product (QIDP) designation to the company's partner Infex Therapeutics for MET-X. According to Infex, MET-X is a resistance bypass treatment which targets Gram-negative Ent...

Medivir AB press release ( OTC:MVRBF ): Q3 GAAP EPS of -SEK 0.27. Revenue of SEK 1.1M (+37.5% Y/Y). Cash flow from operating activities amounted to -SEK 19.7M. Cash and cash equivalents at the end of the period amounted to SEK 142.2M. For further d...

Medivir AB press release ( OTC:MVRBF ): Q2 GAAP EPS of - SEK 0.42. Revenue of SEK 0.5M (-44.4% Y/Y). Outlook: Medivir’s future investments will mainly be in clinical pharmaceutical projects within oncology. It is the assessment of the board and management that e...

MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2022 PR Newswire STOCKHOLM , Aug. 19, 2022 /PRNewswire/ -- The clinical development of fostrox remains the focus April - June Financial summary for the quarter Net turnover amoun...

Medivir AB press release (OTC:MVRBF): Q1 GAAP EPS of -SEK 0.59. Revenue of SEK 0.5M (-94.9% Y/Y). For further details see: Medivir AB GAAP EPS of -SEK 0.59, revenue of SEK 0.5M